AstraZeneca at a glance
AstraZeneca is a global, innovation-driven biopharmaceutical business
Our mission is to make the most meaningful difference to the health of patients through great medicines
We do this with a range of medicines designed to improve patients' health and quality of life around the world
We are committed to developing each activity within our business in a responsible way
Our work is supported by our values and the conduct of employees in working with each other and our stakeholders
We believe that our approach delivers lasting value for patients, society and our shareholders
62,700 62,700 employees worldwide
We are focused on the discovery, development and commercialisation of prescription medicines for six important areas of healthcare
We have a broad product range that includes many leaders in the treatment of the world's most serious illnesses
We have 10 medicines with sales of more than $1 billion each in 2009
We use our scientific and commercial skills to develop a pipeline of innovative new products to meet medical need
| Healthcare area | Key product |
|---|---|
| Cardiovascular | Crestor (for managing cholesterol levels) |
| Gastrointestinal | Nexium (for acid reflux) |
| Infection | Synagis (for RSV, a form of respiratory infection in infants) |
| Neuroscience | Seroquel (for schizophrenia, bipolar disorder and major depressive disorder) |
| Oncology | Arimidex (for breast cancer) |
| Respiratory & Inflammation | Symbicort (for asthma and chronic obstructive pulmonary disease) |
$1bn 10 medicines with sales of over
$1 billion each in 2009
We are committed to working in a spirit of collaboration to achieve our goal of better health for patients
We recognise the value of collaborative work, and so continually seek to develop new ways of working with others who complement our existing skills, enhance our internal innovation or bring extra value to what we do
Our products rely not only on teamwork within AstraZeneca but on working with doctors, patients and other stakeholders to understand what they need and want
We also work with governments and those who pay for healthcare to ensure our products represent value for money
We work with NGOs and others to improve local healthcare in vulnerable communities around the world
60 60 major R&D collaborations in the last three years
We have a global reach but local knowledge, being active in over
100 countries, with a growing presence in emerging markets such as China, Brazil, India and Russia
In 2009 we had sales of $15,981 million in North America,
$12,471 million in Other Established Markets and $4,352 million in Emerging Markets
Combining our disease area expertise with country-specific knowledge helps us to market and sell medicines that best meet local needs
Of our 62,700 employees worldwide, 47% are in Europe, 31% in the Americas and 22% in Asia, Africa and Australasia
Around 11,600 people work in our R&D organisation and we have
17 principal R&D centres in eight countries, including Sweden, the US and the UK
We have 9,500 employees at 20 manufacturing sites in 16 countries
100+ Active in over 100 countries
